

Young-Suk Lim

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/3134983/publications.pdf>

Version: 2024-02-01

206
papers

8,602
citations

57681

46
h-index

60403

85
g-index

212
all docs

212
docs citations

212
times ranked

8421
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 1 | Tenofovir Alafenamide for Drug-Resistant Hepatitis B: A Randomized Trial for Switching From Tenofovir Disoproxil Fumarate. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 427-437.e5. | 2.4 | 33 |
| 2 | Risk of Hepatitis B Virus Reactivation in Patients Treated With Immunotherapy for Anti-cancer Treatment. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 898-907. | 2.4 | 29 |
| 3 | Methodological challenges of performing meta-analyses to compare the risk of hepatocellular carcinoma between chronic hepatitis B treatments. <i>Journal of Hepatology</i> , 2022, 76, 186-194. | 1.8 | 14 |
| 4 | An artificial intelligence model to predict hepatocellular carcinoma risk in Korean and Caucasian patients with chronic hepatitis B. <i>Journal of Hepatology</i> , 2022, 76, 311-318. | 1.8 | 48 |
| 5 | A New Reporting System for Diagnosis of Hepatocellular Carcinoma in Chronic Hepatitis B With Clinical and Gadoteric Acid-enhanced MRI Features. <i>Journal of Magnetic Resonance Imaging</i> , 2022, 55, 1877-1886. | 1.9 | 7 |
| 6 | Abbreviated magnetic resonance imaging vs ultrasound for surveillance of hepatocellular carcinoma in high-risk patients. <i>Liver International</i> , 2022, 42, 2080-2092. | 1.9 | 28 |
| 7 | A risk scoring system to predict clinical events in chronic hepatitis B virus infection: A nationwide cohort study. <i>Journal of Viral Hepatitis</i> , 2022, 29, 115-123. | 1.0 | 3 |
| 8 | Safety of direct oral anticoagulants compared to warfarin in cirrhotic patients with atrial fibrillation. <i>Korean Journal of Internal Medicine</i> , 2022, 37, 555-566. | 0.7 | 6 |
| 9 | Use of hepatitis B virus DNA and liver stiffness in predicting clinical events in patients with chronic hepatitis B. <i>Journal of Viral Hepatitis</i> , 2022, 29, 297-297. | 1.0 | 0 |
| 10 | Stereotactic body radiation therapy as a salvage treatment for single viable hepatocellular carcinoma at the site of incomplete transarterial chemoembolization: a retrospective analysis of 302 patients. <i>BMC Cancer</i> , 2022, 22, 175. | 1.1 | 4 |
| 11 | Review article: switching patients with chronic hepatitis B to tenofovir alafenamide—a review of current data. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 921-943. | 1.9 | 14 |
| 12 | Hypervascular transformation of hepatobiliary phase hypointense nodules without arterial phase hyperenhancement on gadoteric acid-enhanced MRI: long-term follow-up in a surveillance cohort. <i>European Radiology</i> , 2022, 32, 5064-5074. | 2.3 | 2 |
| 13 | Increasing on-treatment hepatocellular carcinoma risk with decreasing baseline viral load in HBsAg-positive chronic hepatitis B. <i>Journal of Clinical Investigation</i> , 2022, 132, . | 3.9 | 17 |
| 14 | The Korean Hepatitis C Virus Care Cascade in a Tertiary Institution: Current Status and Changes in Testing, Link to Care, and Treatment. <i>Gut and Liver</i> , 2022, 16, 964-975. | 1.4 | 4 |
| 15 | Editorial: does TAF have a better or worse safety profile than TDF, to treat hepatitis B? Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 55, 1044-1045. | 1.9 | 1 |
| 16 | Identification of hepatic steatosis in living liver donors by machine learning models. <i>Hepatology Communications</i> , 2022, 6, 1689-1698. | 2.0 | 4 |
| 17 | Efficacy and safety of tenofovir alafenamide versus tenofovir disoproxil fumarate in treatment-naïve chronic hepatitis B. <i>Liver International</i> , 2022, 42, 1517-1527. | 1.9 | 18 |
| 18 | Radiologic Response as a Prognostic Factor in Advanced Hepatocellular Carcinoma with Macroscopic Vascular Invasion after Transarterial Chemoembolization and Radiotherapy. <i>Liver Cancer</i> , 2022, 11, 152-161. | 4.2 | 2 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 19 | Liver Imaging Reporting and Data System Categories: Long-term Imaging Outcomes in a Prospective Surveillance Cohort. <i>Liver International</i> , 2022, , . | 1.9 | 3 |
| 20 | Comparison of Fucose-Specific Lectins to Improve Quantitative AFP-L3 Assay for Diagnosing Hepatocellular Carcinoma Using Mass Spectrometry. <i>Journal of Proteome Research</i> , 2022, 21, 1548-1557. | 1.8 | 10 |
| 21 | Real-world efficacy and safety of cabozantinib in Korean patients with advanced hepatocellular carcinoma: a multicenter retrospective analysis. <i>Therapeutic Advances in Medical Oncology</i> , 2022, 14, 175883592210979. | 1.4 | 7 |
| 22 | Impact of expanding hepatitis B treatment guidelines: A modelling and economic impact analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 519-528. | 1.9 | 14 |
| 23 | Impact of HBsAg seroclearance on late recurrence of hepatitis B virus-related hepatocellular carcinoma after surgical resection. <i>Journal of Hepatology</i> , 2022, 77, 939-946. | 1.8 | 18 |
| 24 | Cost-effectiveness of antiviral treatment in adult patients with immune-tolerant phase chronic hepatitis B. <i>Gut</i> , 2021, 70, 2172-2182. | 6.1 | 30 |
| 25 | Comparison of Long-term Clinical Outcomes Between Spontaneous and Therapy-induced HBsAg Seroclearance. <i>Hepatology</i> , 2021, 73, 2155-2166. | 3.6 | 24 |
| 26 | Tenofovir Versus Entecavir on Recurrence of Hepatitis B Virus-Related Hepatocellular Carcinoma After Surgical Resection. <i>Hepatology</i> , 2021, 73, 661-673. | 3.6 | 77 |
| 27 | REPLY:. <i>Hepatology</i> , 2021, 73, 467-467. | 3.6 | 0 |
| 28 | Reply:. <i>Hepatology</i> , 2021, 73, 1241-1241. | 3.6 | 0 |
| 29 | Porto-sinusoidal vascular disease with portal hypertension versus liver cirrhosis: differences in imaging features on CT and hepatobiliary contrast-enhanced MRI. <i>Abdominal Radiology</i> , 2021, 46, 1891-1903. | 1.0 | 16 |
| 30 | High level of medication adherence is required to lower mortality in patients with chronic hepatitis B taking entecavir: A nationwide cohort study. <i>Journal of Viral Hepatitis</i> , 2021, 28, 353-363. | 1.0 | 9 |
| 31 | Clinical Outcomes with Multikinase Inhibitors after Progression on First-Line Atezolizumab plus Bevacizumab in Patients with Advanced Hepatocellular Carcinoma: A Multinational Multicenter Retrospective Study. <i>Liver Cancer</i> , 2021, 10, 107-114. | 4.2 | 66 |
| 32 | One-year Fibrosis-4 index helps identify minimal HCC risk in non-cirrhotic chronic hepatitis B patients with antiviral treatment. <i>Hepatology International</i> , 2021, 15, 105-113. | 1.9 | 6 |
| 33 | Risk of hepatocellular carcinoma with tenofovir versus entecavir in chronic hepatitis B. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 87. | 3.7 | 1 |
| 34 | Combined <sc>Hepatocellularâ€Cholangiocarcinoma</sc>: Magnetic Resonance Imaging Features and Prognosis According to Risk Factors for Hepatocellular Carcinoma. <i>Journal of Magnetic Resonance Imaging</i> , 2021, 53, 1803-1812. | 1.9 | 9 |
| 35 | Effects of Tenofovir vs Entecavir on Risk of Hepatocellular Carcinoma in Patients With Chronic HBV Infection: A Systematic Review and Meta-analysis. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 246-258.e9. | 2.4 | 71 |
| 36 | Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2021, , . | 2.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 37 | Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular&cholangiocarcinoma. Liver International, 2021, 41, 1398-1408. | 1.9 | 22 |
| 38 | Radiofrequency ablation <i>versus</i> stereotactic body radiation therapy for small (≤ 3 cm) hepatocellular carcinoma: A retrospective comparison analysis. Journal of Gastroenterology and Hepatology (Australia), 2021, 36, 1962-1970. | 1.4 | 14 |
| 39 | Towards a New Horizon for Individualized Surveillance Tools in Hepatocellular Carcinoma. Clinical Gastroenterology and Hepatology, 2021, , . | 2.4 | 0 |
| 40 | Kinetics of the neutrophil&lymphocyte ratio during PD≤1 inhibition as a prognostic factor in advanced hepatocellular carcinoma. Liver International, 2021, 41, 2189-2199. | 1.9 | 26 |
| 41 | Tenofovir disoproxil fumarate on the risk of hepatocellular carcinoma in chronic hepatitis B patients with failure to preceding treatments: A nationwide cohort study. Journal of Viral Hepatitis, 2021, 28, 1150-1159. | 1.0 | 1 |
| 42 | Efficacy and Safety of Glecaprevir/Pibrentasvir in Korean Patients with Chronic Hepatitis C: A Pooled Analysis of Five Phase II/III Trials. Gut and Liver, 2021, 15, 895-903. | 1.4 | 3 |
| 43 | Inclusive Quantification Assay of Serum Des≤3–Carboxyprothrombin Proteoforms for Hepatocellular Carcinoma Surveillance by Targeted Mass Spectrometry. Hepatology Communications, 2021, 5, 1767-1783. | 2.0 | 4 |
| 44 | Entecavir versus tenofovir in patients with chronic hepatitis B: Enemies or partners in the prevention of hepatocellular carcinoma. Clinical and Molecular Hepatology, 2021, 27, 402-412. | 4.5 | 31 |
| 45 | Association of aspirin and statin use with the risk of liver cancer in chronic hepatitis B: A nationwide population–based study. Liver International, 2021, 41, 2777-2785. | 1.9 | 17 |
| 46 | Clinical Study of Single–Stranded Oligonucleotide RO7062931 in Healthy Volunteers and Patients With Chronic Hepatitis B. Hepatology, 2021, 74, 1795-1808. | 3.6 | 24 |
| 47 | IDDF2021-ABS-0077–...Efficacy and safety of tenofovir alafenamide (TAF) vs tenofovir disoproxil fumarate (TDF) in east asian chronic hepatitis B patients following 5-years of treatment. , 2021, , . | | 2 |
| 48 | IDDF2021-ABS-0080–...96-week efficacy and safety of tenofovir disoproxil fumarate (TDF) to tenofovir alafenamide (TAF) switch vs. continued TDF treatment among virologically-suppressed hepatitis B patients of asian ethnicity. , 2021, , . | | 0 |
| 49 | IDDF2021-ABS-0079–...Switching from tenofovir disoproxil fumarate (TDF) and/or other oral antivirals (OAVS) to tenofovir alafenamide (TAF) in virally suppressed chronic hepatitis B (CHB) patients with hepatic impairment: final 2-year efficacy and safety results from a phase 2. , 2021, , . | | 0 |
| 50 | Safety, Pharmacokinetics, and Pharmacodynamics of the Oral TLR8 Agonist Selgantolimod in Chronic Hepatitis B. Hepatology, 2021, 74, 1737-1749. | 3.6 | 27 |
| 51 | Multiple imputation analysis for propensity score matching with missing causes of failure: An application to hepatocellular carcinoma data. Statistical Methods in Medical Research, 2021, 30, 096228022110370. | 0.7 | 1 |
| 52 | Therapeutic vaccine BRIL-179 restores HBV-specific immune responses in patients with chronic HBV in a phase Ib/IIa study. JHEP Reports, 2021, 3, 100361. | 2.6 | 24 |
| 53 | Secondary prevention of hepatitis B <sc>virus–related</sc> hepatocellular carcinoma with current antiviral therapies. Kaohsiung Journal of Medical Sciences, 2021, 37, 262-267. | 0.8 | 5 |
| 54 | Nucleos(t)ide Therapy and Long-Term Outcomes. , 2021, , 287-318. | | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 55 | The role of muscle depletion and visceral adiposity in HCC patients aged 65 and over undergoing TACE. <i>BMC Cancer</i> , 2021, 21, 1164. | 1.1 | 11 |
| 56 | Role of Tumor Biomarkers in the Surveillance of Hepatocellular Carcinoma. <i>Korean journal of gastroenterology = Taehan Sohwagi Hakhoe chi, The</i> , 2021, 78, 284-288. | 0.2 | 1 |
| 57 | Letter: serum hepatitis B virus DNA and risk of hepatocellular carcinoma in patients with chronic hepatitis Bâ€”authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2021, 53, 763-763. | 1.9 | 0 |
| 58 | Safety, pharmacokinetics, and antiviral effects of ABI-H0731, a hepatitis B virus core inhibitor: a randomised, placebo-controlled phase 1 trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 152-166. | 3.7 | 85 |
| 59 | Earlier Alanine Aminotransferase Normalization During Antiviral Treatment Is Independently Associated With Lower Risk of Hepatocellular Carcinoma in Chronic Hepatitis B. <i>American Journal of Gastroenterology</i> , 2020, 115, 406-414. | 0.2 | 29 |
| 60 | Non-enhanced magnetic resonance imaging as a surveillance tool for hepatocellular carcinoma: Comparison with ultrasound. <i>Journal of Hepatology</i> , 2020, 72, 718-724. | 1.8 | 86 |
| 61 | Preliminary safety and antiviral activity of VIR-2218, an X-targeting HBV RNAi therapeutic, in chronic hepatitis B patients. <i>Journal of Hepatology</i> , 2020, 73, S50-S51. | 1.8 | 17 |
| 62 | Effectiveness and Safety of Nivolumab in Childâ€”Pugh B Patients with Hepatocellular Carcinoma: A Real-World Cohort Study. <i>Cancers</i> , 2020, 12, 1968. | 1.7 | 40 |
| 63 | In reply to Huo et al.: Treating small hepatocellular carcinoma: Stereotactic body radiation therapy <i>versus</i> radiofrequency ablation. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 2293-2293. | 1.4 | 0 |
| 64 | East Asia expert opinion on treatment initiation for chronic hepatitis B. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 1540-1550. | 1.9 | 36 |
| 65 | Letter: moderate levels of serum hepatitis B virus DNA alone are not associated with increased risk of hepatocellular carcinoma in chronic hepatitis B patients. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 52, 576-577. | 1.9 | 1 |
| 66 | Tenofovir vs entecavir on post-operative recurrence-free and overall survival of patients with hepatitis B virus-related hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2020, 73, S69. | 1.8 | 9 |
| 67 | Selection of MRI contrast agent and diagnostic criteria for HCC to maximize the advantages of contrast agents. <i>Journal of Hepatology</i> , 2020, 73, 714-715. | 1.8 | 3 |
| 68 | Management of primary hepatic malignancies during the COVID-19 pandemic: recommendations for risk mitigation from a multidisciplinary perspective. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 765-775. | 3.7 | 33 |
| 69 | Proteome Multimarker Panel With Multiple Reaction Monitoringâ€”Mass Spectrometry for Early Detection of Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2020, 4, 753-768. | 2.0 | 3 |
| 70 | Discontinuation of nucleos(t)ide analogues is not associated with a higher risk of HBsAg seroreversion after antiviral-induced HBsAg seroclearance: a nationwide multicentre study. <i>Gut</i> , 2020, 69, 2214-2222. | 6.1 | 20 |
| 71 | Evaluation of transarterial chemoembolization refractoriness in patients with hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0229696. | 1.1 | 17 |
| 72 | Regorafenib Versus Nivolumab After Sorafenib Failure: Realâ€”World Data in Patients With Hepatocellular Carcinoma. <i>Hepatology Communications</i> , 2020, 4, 1073-1086. | 2.0 | 28 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 73 | Clinical outcomes of stereotactic body radiation therapy for small hepatocellular carcinoma. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020, 35, 1953-1959. | 1.4 | 19 |
| 74 | Switching from tenofovir disoproxil fumarate to tenofovir alafenamide in virologically suppressed patients with chronic hepatitis B: a randomised, double-blind, phase 3, multicentre non-inferiority study. <i>The Lancet Gastroenterology and Hepatology</i> , 2020, 5, 441-453. | 3.7 | 85 |
| 75 | Moderate levels of serum hepatitis B virus DNA are associated with the highest risk of hepatocellular carcinoma in chronic hepatitis B patients. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1169-1179. | 1.9 | 50 |
| 76 | Stereotactic body radiation therapy for small (≤ 5 cm) hepatocellular carcinoma not amenable to curative treatment: Results of a single-arm, phase II clinical trial. <i>Clinical and Molecular Hepatology</i> , 2020, 26, 506-515. | 4.5 | 52 |
| 77 | The quick sepsis-related organ failure score has limited value for predicting adverse outcomes in sepsis patients with liver cirrhosis. <i>Korean Journal of Internal Medicine</i> , 2020, 35, 861-872. | 0.7 | 4 |
| 78 | Editorial: hepatitis B DNA thresholds and risk of hepatocellular carcinoma: different number patterns in HBeAg-positive versus HBeAg-negative patients. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2020, 51, 1440-1441. | 1.9 | 1 |
| 79 | Expedited Safety Reporting to Sponsors Through the Implementation of an Alert System for Clinical Trial Management at an Academic Medical Center: Retrospective Design Study. <i>JMIR Medical Informatics</i> , 2020, 8, e14379. | 1.3 | 0 |
| 80 | A simple and clinically applicable model to predict liver-related morbidity after hepatic resection for hepatocellular carcinoma. <i>PLoS ONE</i> , 2020, 15, e0241808. | 1.1 | 2 |
| 81 | IDDF2020-ABS-0060...Impact of prior tenofovir disoproxil fumarate (TDF) treatment duration on tenofovir alafenamide (TAF) safety profile in virally suppressed chronic HBV patients switched from TDF to TAF. , 2020, , . | | 0 |
| 82 | IDDF2020-ABS-0061...Impact of treatment with tenofovir alafenamide (TAF) or tenofovir disoproxil fumarate (TDF) on hepatocellular carcinoma (HCC) incidence in patients with chronic hepatitis B (CHB). , 2020, , . | | 0 |
| 83 | Quantification of Antibody to Hepatitis B Core Antigen to Predict Outcomes of Patients With HBV Infection. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 39-40. | 2.4 | 1 |
| 84 | Letter: risk of developing hepatocellular carcinoma in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. Authors' reply. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 619-620. | 1.9 | 0 |
| 85 | Large-scale viral genome analysis identifies novel clinical associations between hepatitis B virus and chronically infected patients. <i>Scientific Reports</i> , 2019, 9, 10529. | 1.6 | 12 |
| 86 | Comparison of risk of hepatocellular carcinoma between tenofovir and entecavir: One direction or no direction. <i>Journal of Hepatology</i> , 2019, 71, 846-847. | 1.8 | 9 |
| 87 | What should medical students know about artificial intelligence in medicine?. <i>Journal of Educational Evaluation for Health Professions</i> , 2019, 16, 18. | 5.9 | 85 |
| 88 | Validation of US Liver Imaging Reporting and Data System Version 2017 in Patients at High Risk for Hepatocellular Carcinoma. <i>Radiology</i> , 2019, 292, 390-397. | 3.6 | 41 |
| 89 | Surgical resection versus radiofrequency ablation very early-stage HCC (≤ 2 cm Single HCC): A propensity score analysis. <i>Liver International</i> , 2019, 39, 2397-2407. | 1.9 | 36 |
| 90 | Tenofovir disoproxil fumarate reduces hepatocellular carcinoma, decompensation and death in chronic hepatitis B patients with cirrhosis. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 1037-1048. | 1.9 | 54 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Combined transarterial chemoembolization and radiotherapy as a first-line treatment for hepatocellular carcinoma with macroscopic vascular invasion: Necessity to subclassify Barcelona Clinic Liver Cancer stage C. <i>Radiotherapy and Oncology</i> , 2019, 141, 95-100. | 0.3 | 17 |
| 92 | High risk of clinical events in untreated HBeAg-negative chronic hepatitis B patients with high viral load and no significant ALT elevation. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 50, 215-226. | 1.9 | 68 |
| 93 | Notice of Retraction and Replacement. Choi et al. Risk of hepatocellular carcinoma in patients treated with entecavir vs tenofovir for chronic hepatitis B: a Korean nationwide cohort study. <i>JAMA Oncol.</i> 2019;5(1):30-36. <i>JAMA Oncology</i> , 2019, 5, 913. | 3.4 | 4 |
| 94 | Lower Risk of Hepatocellular Carcinoma With Tenofovir vs Entecavir in Patients With Chronic Hepatitis B—in Reply. <i>JAMA Oncology</i> , 2019, 5, 916. | 3.4 | 4 |
| 95 | Arterial subtraction images of gadoxetate-enhanced MRI improve diagnosis of early-stage hepatocellular carcinoma. <i>Journal of Hepatology</i> , 2019, 71, 534-542. | 1.8 | 36 |
| 96 | Long-term clinical outcomes in patients with autoimmune hepatitis according to treatment response in Asian country. <i>Liver International</i> , 2019, 39, 985-994. | 1.9 | 19 |
| 97 | Monotherapy with tenofovir disoproxil fumarate for adefovir-resistant vs. entecavir-resistant chronic hepatitis B: A 5-year clinical trial. <i>Journal of Hepatology</i> , 2019, 71, 35-44. | 1.8 | 29 |
| 98 | Systematic review with meta-analysis: extrahepatic manifestations in chronic hepatitis C virus-infected patients in East Asia. <i>Alimentary Pharmacology and Therapeutics</i> , 2019, 49, 644-653. | 1.9 | 24 |
| 99 | IDDF2019-ABS-0257...Factors and models for predicting posthepatectomy liver failure in patients undergoing hepatic resection for hepatocellular carcinoma. , 2019, , . | | 0 |
| 100 | IDDF2019-ABS-0168...Bone and renal safety are improved in chronic hbv patients 1 year after switching to tenofovir alafenamide (TAF) from tenofovir disoproxil fumarate (TDF). , 2019, , . | | 0 |
| 101 | Intraindividual Comparison between Gadoxetate-Enhanced Magnetic Resonance Imaging and Dynamic Computed Tomography for Characterizing Focal Hepatic Lesions: A Multicenter, Multireader Study. <i>Korean Journal of Radiology</i> , 2019, 20, 1616. | 1.5 | 22 |
| 102 | Longitudinal Assessment of Three Serum Biomarkers to Detect Very Early-Stage Hepatocellular Carcinoma. <i>Hepatology</i> , 2019, 69, 1983-1994. | 3.6 | 127 |
| 103 | Magnetic Resonance Imaging Is Cost-Effective for Hepatocellular Carcinoma Surveillance in High-Risk Patients With Cirrhosis. <i>Hepatology</i> , 2019, 69, 1599-1613. | 3.6 | 70 |
| 104 | Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 23-32. | 2.0 | 62 |
| 105 | Risk of Hepatocellular Carcinoma in Patients Treated With Entecavir vs Tenofovir for Chronic Hepatitis B. <i>JAMA Oncology</i> , 2019, 5, 30. | 3.4 | 219 |
| 106 | Time-dependent reversal of significant intrapulmonary shunt after liver transplantation. <i>Korean Journal of Internal Medicine</i> , 2019, 34, 510-518. | 0.7 | 3 |
| 107 | Liver Imaging Reporting and Data System: Patient Outcomes for Category 4 and 5 Nodules. <i>Radiology</i> , 2018, 287, 515-524. | 3.6 | 17 |
| 108 | Response to: "Prognosis of immune-tolerant phase chronic hepatitis B" by Chu and Liaw. <i>Gut</i> , 2018, 67, 988.2-989. | 6.1 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 109 | 96-weeks treatment of tenofovir alafenamide vs. tenofovir disoproxil fumarate for hepatitis B virus infection. <i>Journal of Hepatology</i> , 2018, 68, 672-681. | 1.8 | 291 |
| 110 | Stereotactic body radiation therapy using a respiratory-gated volumetric-modulated arc therapy technique for small hepatocellular carcinoma. <i>BMC Cancer</i> , 2018, 18, 416. | 1.1 | 30 |
| 111 | Efficacy and Safety of Transarterial Chemoembolization Plus External Beam Radiotherapy vs Sorafenib in Hepatocellular Carcinoma With Macroscopic Vascular Invasion. <i>JAMA Oncology</i> , 2018, 4, 661. | 3.4 | 311 |
| 112 | Temporal improvement in survival of patients with hepatocellular carcinoma in a hepatitis B virus-endemic population. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2018, 33, 475-483. | 1.4 | 46 |
| 113 | Outcome comparison of liver transplantation for hepatitis A-related versus hepatitis B-related acute liver failure in adult recipients. <i>Clinical Transplantation</i> , 2018, 32, e13140. | 0.8 | 15 |
| 114 | High risk of hepatocellular carcinoma and death in patients with immune-tolerant-phase chronic hepatitis B. <i>Gut</i> , 2018, 67, 945-952. | 6.1 | 176 |
| 115 | Impact of ledipasvir/sofosbuvir on the work productivity of genotype 1 chronic hepatitis C patients in Asia. <i>Journal of Viral Hepatitis</i> , 2018, 25, 228-235. | 1.0 | 12 |
| 116 | Performing Gadoteric Acid-Enhanced MRI After CT for Guiding Curative Treatment of Early-Stage Hepatocellular Carcinoma: A Cost-Effectiveness Analysis. <i>American Journal of Roentgenology</i> , 2018, 210, W63-W69. | 1.0 | 11 |
| 117 | Poor adherence to hepatocellular carcinoma surveillance: A systematic review and meta-analysis of a complex issue. <i>Liver International</i> , 2018, 38, 503-514. | 1.9 | 61 |
| 118 | Prognostic Implication of Inflammation-based Prognostic Scores in Patients with Intrahepatic Cholangiocarcinoma Treated with First-line Gemcitabine plus Cisplatin. <i>Investigational New Drugs</i> , 2018, 36, 496-502. | 1.2 | 9 |
| 119 | The effect of interferon-free regimens on health-related quality of life in East Asian patients with chronic hepatitis C. <i>Liver International</i> , 2018, 38, 1179-1187. | 1.9 | 17 |
| 120 | Association between non-alcoholic fatty liver disease and cancer incidence rate. <i>Journal of Hepatology</i> , 2018, 68, 140-146. | 1.8 | 185 |
| 121 | IDDF2018-ABS-0168...Utility of FDG-PET/CT in pre-transplantation workup of the potential liver recipient with hepatocellular carcinoma. , 2018, , . | | 0 |
| 122 | IDDF2018-ABS-0137...Longitudinal assessment of alpha-fetoprotein, lectin-reactive alpha-fetoprotein, and des-gamma-carboxy prothrombin for the early detection of hepatocellular carcinoma. , 2018, , . | | 0 |
| 123 | IDDF2018-ABS-0235...Reappraisal of the accuracy of diagnostic criteria for spontaneous bacterial peritonitis in cirrhotic patients with or without hepatocellular carcinoma: a preliminary result. , 2018, , . | | 0 |
| 124 | Anti-viral therapy is associated with improved survival but is underutilised in patients with hepatitis B virus-related hepatocellular carcinoma: real-world east and west experience. <i>Alimentary Pharmacology and Therapeutics</i> , 2018, 48, 44-54. | 1.9 | 34 |
| 125 | No Resistance to Tenofovir Alafenamide Detected through 96 Weeks of Treatment in Patients with Chronic Hepatitis B Infection. <i>Antimicrobial Agents and Chemotherapy</i> , 2018, 62, . | 1.4 | 41 |
| 126 | The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection. <i>PLoS ONE</i> , 2018, 13, e0198138. | 1.1 | 28 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 127 | Predictors of HBeAg loss and seroconversion by baseline clinical features and viral deep sequencing after 144 weeks of treatment with Tenofovir Alafenamide or Tenofovir Disoproxil Fumarate. <i>Journal of Hepatology</i> , 2018, 68, S523-S524. | 1.8 | 1 |
| 128 | Sofosbuvir and ledipasvir are associated with high sustained virologic response and improvement of health-related quality of life in East Asian patients with hepatitis C virus infection. <i>Journal of Viral Hepatitis</i> , 2018, 25, 1429-1437. | 1.0 | 16 |
| 129 | HCV phylogenetic signature and prevalence of pretreatment NS5A and NS5B NI-Resistance associated substitutions in HCV-Infected patients in Mainland China. <i>Antiviral Research</i> , 2018, 158, 178-184. | 1.9 | 17 |
| 130 | Sustained efficacy of adjuvant immunotherapy with cytokine-induced killer cells for hepatocellular carcinoma: an extended 5-year follow-up. <i>Journal of Hepatology</i> , 2018, 68, S37-S38. | 1.8 | 6 |
| 131 | Prognostic implications of hepatitis B virus infection in intrahepatic cholangiocarcinoma treated with first-line gemcitabine plus cisplatin. <i>International Journal of Biological Markers</i> , 2018, 33, 432-438. | 0.7 | 2 |
| 132 | Chronic hepatitis B infection and non-hepatocellular cancers: A hospital registry-based, case-control study. <i>PLoS ONE</i> , 2018, 13, e0193232. | 1.1 | 42 |
| 133 | Comparison of surgical resection versus transarterial chemoembolization with additional radiation therapy in patients with hepatocellular carcinoma with portal vein invasion. <i>Clinical and Molecular Hepatology</i> , 2018, 24, 144-150. | 4.5 | 13 |
| 134 | Clinical impact of preoperative brain MR angiography and MR imaging in candidates for liver transplantation: a propensity score-matching study in a single institution. <i>European Radiology</i> , 2017, 27, 3532-3541. | 2.3 | 6 |
| 135 | Clinical validity of Metroticket calculator in transplant patients undergoing prior chemoembolization for hepatocellular carcinoma. <i>Hepatology International</i> , 2017, 11, 209-219. | 1.9 | 1 |
| 136 | Impact of emergency adult living donor liver transplantation on the survival of patients with antituberculosis therapy-induced acute liver failure. <i>Liver Transplantation</i> , 2017, 23, 845-846. | 1.3 | 4 |
| 137 | Higher risk of hepatocellular carcinoma in chronic hepatitis B vs chronic hepatitis C after achievement of virologic response. <i>Journal of Viral Hepatitis</i> , 2017, 24, 990-997. | 1.0 | 9 |
| 138 | Increasing burden of liver cancer despite extensive use of antiviral agents in a hepatitis B virus-endemic population. <i>Hepatology</i> , 2017, 66, 1454-1463. | 3.6 | 92 |
| 139 | New intermediate-stage subclassification for patients with hepatocellular carcinoma treated with transarterial chemoembolization. <i>Liver International</i> , 2017, 37, 1861-1868. | 1.9 | 69 |
| 140 | Monotherapy with tenofovir disoproxil fumarate for multiple drug-resistant chronic hepatitis B: 3-year trial. <i>Hepatology</i> , 2017, 66, 772-783. | 3.6 | 37 |
| 141 | Post-resection Prognosis of Combined Hepatocellular Carcinoma-Cholangiocarcinoma According to the 2010 WHO Classification. <i>World Journal of Surgery</i> , 2017, 41, 1347-1357. | 0.8 | 19 |
| 142 | Genetic-based Risk Assessment for Hepatocellular Carcinoma in Patients with Hepatitis C: Where Do We Stand?. <i>EBioMedicine</i> , 2017, 15, 6-7. | 2.7 | 3 |
| 143 | Tumor Volume Doubling Time as a Dynamic Prognostic Marker for Patients with Hepatocellular Carcinoma. <i>Digestive Diseases and Sciences</i> , 2017, 62, 2923-2931. | 1.1 | 29 |
| 144 | Telbivudine versus entecavir in patients with undetectable hepatitis B virus DNA: a randomized trial. <i>BMC Gastroenterology</i> , 2017, 17, 15. | 0.8 | 11 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 145 | The impact of hepatitis C virus outside the liver: Evidence from Asia. <i>Liver International</i> , 2017, 37, 159-172. | 1.9 | 38 |
| 146 | MRI With Liver-Specific Contrast for Surveillance of Patients With Cirrhosis at High Risk of Hepatocellular Carcinoma. <i>JAMA Oncology</i> , 2017, 3, 456. | 3.4 | 241 |
| 147 | Characteristics, Prevention, and Management of Hepatitis B Virus (HBV) Reactivation in HBV-Infected Patients Who Require Immunosuppressive Therapy. <i>Journal of Infectious Diseases</i> , 2017, 216, S778-S784. | 1.9 | 24 |
| 148 | Management of Antiviral Resistance in Chronic Hepatitis B. <i>Gut and Liver</i> , 2017, 11, 189-195. | 1.4 | 39 |
| 149 | Clinical features and outcomes of patients with hepatocellular carcinoma complicated with bile duct invasion. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 160-169. | 4.5 | 33 |
| 150 | Lamivudine: fading into the mists of time. <i>Clinical and Molecular Hepatology</i> , 2017, 23, 314-315. | 4.5 | 0 |
| 151 | Comprehensive outcomes of on- and off-antiviral prophylaxis in hepatitis B patients undergoing cancer chemotherapy: A competing risks analysis. <i>Journal of Medical Virology</i> , 2016, 88, 1576-1586. | 2.5 | 9 |
| 152 | All-oral daclatasvir plus asunaprevir for chronic hepatitis C virus (HCV) genotype 1b infection: a sub-analysis in Asian patients from the <sc>HALLMARK DUAL</sc> study. <i>Liver International</i> , 2016, 36, 1433-1441. | 1.9 | 25 |
| 153 | Clinical characteristics and outcomes of spontaneous bacterial peritonitis caused by <i>Enterobacter</i> species versus <i>Escherichia coli</i> : a matched case-control study. <i>BMC Infectious Diseases</i> , 2016, 16, 252. | 1.3 | 5 |
| 154 | A phase IIIb study of ledipasvir/sofosbuvir fixed-dose combination tablet in treatment-naïve and treatment-experienced Korean patients chronically infected with genotype 1 hepatitis C virus. <i>Hepatology International</i> , 2016, 10, 947-955. | 1.9 | 17 |
| 155 | Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of HBeAg-positive chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 185-195. | 3.7 | 336 |
| 156 | Tenofovir alafenamide versus tenofovir disoproxil fumarate for the treatment of patients with HBeAg-negative chronic hepatitis B virus infection: a randomised, double-blind, phase 3, non-inferiority trial. <i>The Lancet Gastroenterology and Hepatology</i> , 2016, 1, 196-206. | 3.7 | 377 |
| 157 | Validation and reappraisal of the assessment for retreatment with transarterial chemoembolization score for unresectable non-metastatic hepatocellular carcinoma in a hepatitis b virus-endemic region. <i>European Radiology</i> , 2016, 26, 3510-3518. | 2.3 | 7 |
| 158 | Clinical significance of fatty liver disease induced by tamoxifen and toremifene in breast cancer patients. <i>Breast</i> , 2016, 28, 67-72. | 0.9 | 33 |
| 159 | Clinical characteristics and potential aetiologies of non- non hepatocellular carcinoma in hepatitis B virus endemic area. <i>Liver International</i> , 2016, 36, 1351-1361. | 1.9 | 19 |
| 160 | Tenofovir monotherapy versus tenofovir and entecavir combination therapy in patients with entecavir-resistant chronic hepatitis B with multiple drug failure: results of a randomised trial. <i>Gut</i> , 2016, 65, 852-860. | 6.1 | 70 |
| 161 | Process Innovation Improves Trial Operation Efficiency. <i>Therapeutic Innovation and Regulatory Science</i> , 2016, 50, 510-514. | 0.8 | 0 |
| 162 | Diagnostic criteria for hepatocellular carcinoma $\geq 1/2$ cm with hepatocyte-specific contrast-enhanced magnetic resonance imaging. <i>Journal of Hepatology</i> , 2016, 64, 1099-1107. | 1.8 | 93 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 163 | Absence of Benefit of Transcatheter Arterial Chemoembolization (TACE) in Patients with Resectable Solitary Hepatocellular Carcinoma. <i>World Journal of Surgery</i> , 2016, 40, 1200-1210. | 0.8 | 25 |
| 164 | Tenofovir monotherapy versus tenofovir and entecavir combination therapy in adefovir-resistant chronic hepatitis B patients with multiple drug failure: results of a randomised trial. <i>Gut</i> , 2016, 65, 1042-1051. | 6.1 | 76 |
| 165 | Risk prediction for patients with hepatocellular carcinoma undergoing chemoembolization: development of a prediction model. <i>Liver International</i> , 2016, 36, 92-99. | 1.9 | 64 |
| 166 | Role of transarterial chemoembolization in relation with sorafenib for patients with advanced hepatocellular carcinoma. <i>Oncotarget</i> , 2016, 7, 74303-74313. | 0.8 | 19 |
| 167 | Apoptosis of Hepatitis B Virus-expressing Liver Tumor Cells Induced by a High Concentration of Nucleos(t)ide Analogue. <i>Anticancer Research</i> , 2016, 36, 6059-6070. | 0.5 | 6 |
| 168 | Intimate association of visceral obesity with non-alcoholic fatty liver disease in healthy Asians: A case-control study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2015, 30, 1666-1672. | 1.4 | 35 |
| 169 | Alpha-fetoprotein normalization as a prognostic surrogate in small hepatocellular carcinoma after stereotactic body radiotherapy: a propensity score matching analysis. <i>BMC Cancer</i> , 2015, 15, 987. | 1.1 | 14 |
| 170 | Adjuvant Immunotherapy With Autologous Cytokine-Induced Killer Cells for Hepatocellular Carcinoma. <i>Gastroenterology</i> , 2015, 148, 1383-1391.e6. | 0.6 | 371 |
| 171 | Optimal methods for measuring eligibility for liver transplant in hepatocellular carcinoma patients undergoing transarterial chemoembolization. <i>Journal of Hepatology</i> , 2015, 62, 1076-1084. | 1.8 | 21 |
| 172 | Response to Letter Regarding Article, "Prevalence and Prediction of Coronary Artery Disease in Patients With Liver Cirrhosis: A Registry-Based Matched Case-Control Study". <i>Circulation</i> , 2015, 132, e19. | 1.6 | 1 |
| 173 | Comparison of Chemoembolization with and without Radiation Therapy and Sorafenib for Advanced Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: A Propensity Score Analysis. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 320-329.e6. | 0.2 | 75 |
| 174 | The oral toll-like receptor-7 agonist GS-9620 in patients with chronic hepatitis B virus infection. <i>Journal of Hepatology</i> , 2015, 63, 320-328. | 1.8 | 170 |
| 175 | A review of the burden of hepatitis C virus infection in China, Japan, South Korea and Taiwan. <i>Hepatology International</i> , 2015, 9, 378-390. | 1.9 | 82 |
| 176 | Incidence of hepatocellular carcinoma after HBsAg seroclearance in chronic hepatitis B patients: A need for surveillance. <i>Journal of Hepatology</i> , 2015, 62, 1092-1099. | 1.8 | 114 |
| 177 | Evaluation of Early-Stage Hepatocellular Carcinoma by Magnetic Resonance Imaging With Gadoteric Acid Detects Additional Lesions and Increases Overall Survival. <i>Gastroenterology</i> , 2015, 148, 1371-1382. | 0.6 | 106 |
| 178 | A Patient-Based Nomogram for Predicting Overall Survival after Radiofrequency Ablation for Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1787-1794.e1. | 0.2 | 13 |
| 179 | Nomograms for Predicting Outcomes after Chemoembolization in Patients with Nonmetastatic Hepatocellular Carcinoma. <i>Journal of Vascular and Interventional Radiology</i> , 2015, 26, 1093-1101.e1. | 0.2 | 4 |
| 180 | Initial human experience of endoscopic ultrasound-guided photodynamic therapy with a novel photosensitizer and a flexible laser-light catheter. <i>Endoscopy</i> , 2015, 47, 1035-1038. | 1.0 | 70 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 181 | Propensity Score Matching Analysis of Changes in Alpha-Fetoprotein Levels after Combined Radiotherapy and Transarterial Chemoembolization for Hepatocellular Carcinoma with Portal Vein Tumor Thrombus. <i>PLoS ONE</i> , 2015, 10, e0135298. | 1.1 | 8 |
| 182 | Fibroblast growth factor receptor isotype expression and its association with overall survival in patients with hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2015, 21, 60. | 4.5 | 23 |
| 183 | Hepatoid differentiation in renal cell carcinoma: a rare histologic pattern with clinical significance. <i>Annals of Diagnostic Pathology</i> , 2014, 18, 363-368. | 0.6 | 9 |
| 184 | Clinicobiochemical prediction of biopsy-proven cases of severe hepatic fibrosis in patients with chronic hepatitis C infection. <i>BMJ Open</i> , 2014, 4, e006255. | 0.8 | 2 |
| 185 | Clinical implications of preoperative and intraoperative liver biopsies for evaluating donor steatosis in living related liver transplantation. <i>Liver Transplantation</i> , 2014, 20, 437-445. | 1.3 | 32 |
| 186 | Prevalence and Prediction of Coronary Artery Disease in Patients With Liver Cirrhosis. <i>Circulation</i> , 2014, 130, 1353-1362. | 1.6 | 87 |
| 187 | HBsAg seroclearance after nucleoside analogue therapy in patients with chronic hepatitis B: clinical outcomes and durability. <i>Gut</i> , 2014, 63, 1325-1332. | 6.1 | 319 |
| 188 | Mortality, Liver Transplantation, and Hepatocellular Carcinoma Among Patients With Chronic Hepatitis B Treated With Entecavir vs Lamivudine. <i>Gastroenterology</i> , 2014, 147, 152-161. | 0.6 | 133 |
| 189 | Role of 15-hydroxyprostaglandin dehydrogenase down-regulation on the prognosis of hepatocellular carcinoma. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 28. | 4.5 | 2 |
| 190 | No association between the IL28B SNP and response to peginterferon plus ribavirin combination treatment in Korean chronic hepatitis C patients. <i>Clinical and Molecular Hepatology</i> , 2014, 20, 177. | 4.5 | 4 |
| 191 | Clinical Features, Image Findings, and Prognosis of Inflammatory Pseudotumor of the Liver: A Multicenter Experience of 45 Cases. <i>Gut and Liver</i> , 2014, 8, 58-63. | 1.4 | 64 |
| 192 | Optimal Measurement Modality and Method for Evaluation of Responses to Transarterial Chemoembolization of Hepatocellular Carcinoma Based on Enhancement Criteria. <i>Journal of Vascular and Interventional Radiology</i> , 2013, 24, 316-325. | 0.2 | 33 |
| 193 | Randomized Trial of the Virologic Response during up to Two Years of Entecavir-Adefovir Combination Therapy in Multiple-Drug-Refractory Chronic Hepatitis B Virus Patients. <i>Antimicrobial Agents and Chemotherapy</i> , 2013, 57, 3369-3374. | 1.4 | 10 |
| 194 | A Case of Hemolytic Uremic Syndrome after Transarterial Chemoembolization with Cisplatin. <i>Korean Journal of Medicine</i> , 2013, 85, 67. | 0.1 | 0 |
| 195 | Entecavir plus Adefovir Combination Treatment for Chronic Hepatitis B Patients after Failure of Nucleoside/Nucleotide Analogues. <i>Antiviral Therapy</i> , 2012, 17, 53-60. | 0.6 | 21 |
| 196 | Randomized Trial of Entecavir plus Adefovir in Patients with Lamivudine-Resistant Chronic Hepatitis B Who Show Suboptimal Response to Lamivudine plus Adefovir. <i>Antimicrobial Agents and Chemotherapy</i> , 2012, 56, 2941-2947. | 1.4 | 26 |
| 197 | Which Response Criteria Best Help Predict Survival of Patients with Hepatocellular Carcinoma Following Chemoembolization? A Validation Study of Old and New Models. <i>Radiology</i> , 2012, 262, 708-718. | 3.6 | 239 |
| 198 | Practical Approach to Endoscopic Management for Bleeding Gastric Varices. <i>Korean Journal of Radiology</i> , 2012, 13, S40. | 1.5 | 8 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|-----|-----------|
| 199 | Estimation of the healthy upper limits for serum alanine aminotransferase in Asian populations with normal liver histology. <i>Hepatology</i> , 2010, 51, 1577-1583. | 3.6 | 152 |
| 200 | Efficacy of entecavir in treatment-naïve patients with hepatitis B virus-related decompensated cirrhosis. <i>Journal of Hepatology</i> , 2010, 52, 176-182. | 1.8 | 244 |
| 201 | Efficacy of entecavir in patients with chronic hepatitis B resistant to both lamivudine and adefovir or to lamivudine alone. <i>Hepatology</i> , 2009, 50, 1064-1071. | 3.6 | 59 |
| 202 | Current status of liver disease in Korea: Hepatitis C. <i>The Korean Journal of Hepatology</i> , 2009, 15, S25. | 1.5 | 21 |
| 203 | Susceptibility to type 1 autoimmune hepatitis is associated with shared amino acid sequences at positions 70-74 of the HLA-DRB1 molecule. <i>Journal of Hepatology</i> , 2008, 48, 133-139. | 1.8 | 49 |
| 204 | Switch of cadherin expression from E- to N-type during the activation of rat hepatic stellate cells. <i>Histochemistry and Cell Biology</i> , 2007, 127, 149-160. | 0.8 | 44 |
| 205 | Increased risk of adefovir resistance in patients with lamivudine-resistant chronic hepatitis B after 48 weeks of adefovir dipivoxil monotherapy. <i>Hepatology</i> , 2006, 43, 1385-1391. | 3.6 | 302 |
| 206 | Current Antiviral Therapy for Chronic Hepatitis B. <i>Journal of Korean Medical Science</i> , 2004, 19, 489. | 1.1 | 14 |